Knight Disposes of Shares of Pediapharm Inc.
MONTREAL, QUEBEC–(Marketwired – Jan 13, 2017) – This press release is being disseminated by Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a specialty pharmaceutical company at the address of 3400 De Maisonneuve Blvd. W., Suite 1055, Montreal, Quebec H3Z 3B8, as required by National Instrument 62-103 – The Early Warning System and Related Take Over Bid and […]
API Is Core to Knight’s Successful Investment
MONTREAL, QUEBEC–(Marketwired – Jan 9, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has successfully exited its investment in Apicore Inc. (“Apicore”), a promising active pharmaceutical ingredient (“API”) manufacturer, after Apicore prepaid the balance of Knight’s US$6.5 million secured loan issued in July 2014. In addition, […]
Knight Creates Many GUD Synergies with its Partner
MONTREAL, QUEBEC–(Marketwired – Dec 28, 2016) – Knight Therapeutics Inc. (TSX:GUD) announced today that, through one of its wholly-owned subsidiaries (“Knight”), it has committed to invest up to US$2 million as a lead order toward the purchase of common shares of Synergy CHC Corp (“Synergy”) (OTCQB:SNYR) conditional on Synergy meeting certain fundraising targets in 2017. […]
Knight Adds New Dimension to 3D Signatures Partnership
MONTREAL, QUEBEC–(Marketwired – Dec 19, 2016) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that it invested $180,000 in 3D Signatures Inc. (TSX VENTURE:DXD) (“3DS”) as part of a brokered private placement of approximately $3.9 million. As consideration, Knight received 240,000 common shares of 3DS and warrants to purchase […]
Knight Therapeutics Announces Exclusive License Agreement with AstraZeneca for Movantik/Moventig(R) in Canada and Israel
MONTREAL, QUEBEC–(Marketwired – Dec 15, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company today announced the signing of an exclusive license agreement with AstraZeneca, for the rights to Movantik (naloxegol) in Canada and Israel. The financial terms of the agreement were not disclosed. Movantik, the first once-daily oral peripherally-acting mu-opioid […]
Knight Reports Third Quarter 2016 Results
MONTREAL, QUEBEC–(Marketwired – Nov 10, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2016. All figures are in thousands of Canadian dollars except for share and per share amounts. Third Quarter 2016 Highlights Reported revenues and […]
Knight to Present at the 15th Annual CIBC Eastern Institutional Investor Conference in Montreal
MONTREAL, QUEBEC–(Marketwired – Sep 19, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Jeffrey Kadanoff, Chief Financial Officer, is scheduled to present at the 15th Annual CIBC Eastern Institutional Investor Conference on Thursday, September 22, 2016 at 2:45 pm ET at Le Centre Sheraton Montreal Hotel in […]
Ink Dry on 3D Signatures Partnership with Knight
MONTREAL, QUEBEC–(Marketwired – Sep 9, 2016) – Knight Therapeutics Inc. (“Knight”)(TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that it has closed on its previously disclosed $1 million equity investment in 3D Signatures Inc. (“3D Signatures”), a biotechnology company with a mature technology platform for personalized medical diagnostics and prognostics, following the completion of […]
Knight Therapeutics Inc.: INTEGA Skin Primed for Crescita (Italian for Growth)
MONTREAL, QUEBEC–(Marketwired – Sep 1, 2016) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that its strategic partner INTEGA Skin Sciences Inc. (“INTEGA”), a Montreal-based dermatology company, has been acquired by Crescita Therapeutics Inc. (“Crescita”) (TSX:CTX) for base consideration of $8.0 million payable in Crescita common shares valued at […]
A Knight is Reborn
MONTREAL, CANADA–(Marketwired – Aug 17, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today announced that Samira Sakhia, former CFO of Paladin Labs Inc. (“Paladin”), will be joining the Knight team as President and member of the Board of Directors. In her new role, beginning on August 31, 2016, Samira […]
